Switching from reservoir to matrix systems for the transdermal delivery of fentanyl: A prospective, multicenter pilot study in outpatients with chronic pain

Rainer Freynhagen, Hans Jürgen Von Giesen, Peter Busche, Rainer Sabatowski, Christhoph Konrad, Stefan Grond

Research output: Contribution to journalShort surveypeer-review

41 Scopus citations

Abstract

Matrix systems for transdermal fentanyl will replace the reservoir systems in Europe. In an industry-independent, prospective, multicenter pilot study, 46 outpatients with chronic pain were asked to assess pain intensity, sleep interference, adverse events, and multiple secondary parameters during administration of the last reservoir and the first two matrix patches. There was no difference in pain intensity, sleep interference, and the rate of adverse events between both systems. Self assessment on a 6-step numeric rating scale (1 = very good, 6 = insufficient) comparing the two systems (reservoir vs. matrix) showed that skin compatibility (2.6 vs. 1.5), adhesive properties (3.2 vs. 1.8), wearability/comfort (2.8 vs. 1.5), and general satisfaction (2.5 vs. 1.8) improved significantly with the new matrix technology. At study endpoint, 91% of patients preferred the matrix system for future use. The new fentanyl matrix system is characterized by a high level of general satisfaction, ease of use, patient acceptance, and improved skin compatibility. Reservoir and matrix systems appear to have comparable efficacy and safety so that outpatients can be switched directly from the reservoir to the matrix system without difficulties and new dose titration.

Original languageEnglish
Pages (from-to)289-297
Number of pages9
JournalJournal of Pain and Symptom Management
Volume30
Issue number3
DOIs
StatePublished - Sep 2005
Externally publishedYes

Keywords

  • Chronic pain
  • Fentanyl
  • Matrix
  • Opioid side effects
  • Reservoir
  • Transdermal therapeutic systems

Fingerprint

Dive into the research topics of 'Switching from reservoir to matrix systems for the transdermal delivery of fentanyl: A prospective, multicenter pilot study in outpatients with chronic pain'. Together they form a unique fingerprint.

Cite this